No Data
No Data
Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush
Apogee Therapeutics Analyst Ratings
Apogee Therapeutics Unveils Promising Phase 1 Trial Results
Express News | Apogee Therapeutics Announces Results up to 9 Months From Phase 1 Trial of Apg777, Its Novel Half-Life Extended Anti-Il-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
Apogee Therapeutics Announces Results Up to 9 Months From Phase 1 Trial of APG777, Its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting